IDENTIFICATION OF A NOVEL POTENTIAL TUMOR MARKER

新型潜在肿瘤标志物的鉴定

• 批准号: 6298856
• 负责人: Yu Geng
• 金额: $ 13.38万
• 依托单位: PROSCI, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-01-18 至 2001-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298856
• 关键词: biomarker; immunoaffinity chromatography; neoplasm /cancer diagnosis; neoplastic cell; nucleic acid sequence; oncoproteins; protein purification; protein structure function; tissue /cell culture; tumor antigens; western blottings

DESCRIPTION: Cancer remains the second leading cause of death in developed countries. A cancer-associated protein was recently discovered during evaluation of antibodies. This protein, like telomerase, was abundantly expressed in 85 percent of tumor cell lines and malignant tumor tissues from patients with lung, breast, brain, or kidney cancer but was detected in only 3.4 percent of normal cells and tissues. It has the features of oncofetal proteins and telomerase but is identical neither to telomerase nor to the protein from which the antibody generating peptide was selected. Thus, this protein appears to be a novel cancer antigen. The expression levels of the protein in a variety of cancer tissues, particularly lung cancer, will be characterized in this proposal. It will be identified by protein purification using a combination of immunoaffinity chromatography and 2D gel separation and sequencing of the purified protein and digested peptides, by phage expression library screening and cDNA sequencing, and by bioinformatic approach. The long-term objectives are to isolate the gene encoding this protein, to develop screening and diagnostic kits, and to define a therapeutic target for cancer. This protein has a large market potential for the development of diagnostic kits and the design of therapeutic drugs for cancer. PROPOSED COMMERCIAL APPLICATION: Characterization and Identification of this novel cancer-associated protein has potential not only in screening diagnosis, prognosis, and monitoring of cancer, but also has potential in molecular and genetic studies of tumor development as well as in being a target for cancer therapy. This novel cancer-associated protein has a large market potential for the development of reserch reagents, diagnostic kits, and therapeutic drugs for cancer.

癌症仍然是发达国家的第二大死亡原因。 国家一种与癌症相关的蛋白质最近被发现， 抗体的评估。这种蛋白质，像端粒酶一样， 在85%的肿瘤细胞系和恶性肿瘤组织中表达， 肺癌、乳腺癌、脑癌或肾癌患者，但仅在 3.4正常细胞和组织的百分比。它具有癌胚的特征 蛋白质和端粒酶，但既不相同的端粒酶，也不相同的 从其中选择抗体产生肽的蛋白质。因此，这 蛋白质似乎是一种新的癌抗原。的表达水平 蛋白质在各种癌症组织中，特别是肺癌，将被 这一提案的特点。它将通过蛋白质纯化来鉴定 使用免疫亲和层析和2D凝胶分离的组合， 通过噬菌体表达对纯化的蛋白质和消化的肽进行测序 文库筛选和cDNA测序，并通过生物信息学方法。的 长期目标是分离编码这种蛋白质的基因， 筛选和诊断试剂盒，并确定癌症的治疗靶点。 该蛋白具有很大的市场潜力，可用于诊断 试剂盒和癌症治疗药物的设计。 拟定商业应用： 这种新的癌症相关蛋白的表征和鉴定具有潜力 不仅在癌症的筛查诊断、预后和监测方面， 在肿瘤发展的分子和遗传学研究中， 疗法 这种新的癌症相关蛋白具有很大的市场开发潜力 癌症的研究试剂、诊断试剂盒和治疗药物。